Press releases
- Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
- Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting
- Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
- Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
- Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
More ▼
Key statistics
As of last trade Blueprint Medicines Corp (2L9:FRA) traded at 101.15, -1.03% below its 52-week high of 102.20, set on Jul 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 101.15 |
---|---|
High | 101.15 |
Low | 101.15 |
Bid | 101.85 |
Offer | 103.95 |
Previous close | 100.10 |
Average volume | 335.89 |
---|---|
Shares outstanding | 62.62m |
Free float | 62.04m |
P/E (TTM) | -- |
Market cap | 6.91bn USD |
EPS (TTM) | -4.82 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 07:03 BST.
More ▼